|
|
테두리
|
|
 |
bswWwGHKRdpBqAugnn |
 |
128 |
|
 |
| An envelope http://thumbzilla.fun/ thumb zilla Analysts at Cowen and Co initiated coverage of thebiotechnology company with an "outperform" rating, saying thecompany's experimental anticoagulant REG1 could be moreeffective than bivalirudin, a competing drug sold by TheMedicine Co under the brand name Angiomax. |
|
 |
Ramiro |
 |
2019-06-07 15:04:08 |
|
|
|
|
|
|
|
|
|
